Beginning March 15, 2019, all the Life Sciences Organizations must align their nonclinical datasets with SENDIG 3.1 (Standard for Exchange of Nonclinical Data). However, as per the PhUSE 2018 report, over 41% of Life Sciences Organizations are either not ready for SENDIG v3.1 or intend to have ad-hoc strategies for SENDIG v3.1 submissions. Nearly half the time, the sponsor organizations are facing issues while exchanging and consolidating SEND data with the CROs. Companies that are SENDIG ready are facing significant data challenges resulting in submission delays and a large consulting spend to make data reportable.

With the introduction of Labwise XD and the upgraded version of Savante that works seamlessly with Pristima XD and other pre-clinical data management solutions, Xybion established the right solution for Life Sciences Organizations to streamline their nonclinical datasets in compliance with the latest standards of CDISC-SEND submissions. In recent years, Xybion’s has produced over 1000 SEND v3.0 submissions. Now, its fully integrated, automated, and intelligent products and services will produce both v3.0 for ongoing studies and v3.1-compliant datasets for studies that run in any pre-clinical systems.

Kamal Biswas, President, and COO of Xybion said “The SEND-as-a-service business has been an exciting growth opportunity for Xybion. From my consulting experience, I could understand that industry needed to solve this problem by combining technology and services. The early automated detection and correction of data issues can make the process much more efficient, error-free, cost-effective, and significantly reduce data integrity issues. We thank our client community which provided detailed guidance and assistance throughout the six-month beta testing period that led up to the release; this beta program was invaluable and assures the functionality and quality datasets to be submitted to the FDA.”

Xybion offers SEND-related services to companies looking to improve their current operations and companies with limited expertise or SEND utilities in-house. Carlos Frade, VP of Pre-clinical R&D Solutions, stated “For those clients who conduct preclinical studies without the use of Pristima XD, or who utilize CROs that do not provide SEND-compliant submission datasets, Xybion can provide this expertise immediately and cost-effectively. Our arsenal of tools has been greatly expanded with this release.”

Visit us at booth #4, if you are attending ESTP Congress.

About Xybion Corporation

Xybion is the leading provider of software, services, and consulting for global corporations operating in highly regulated industries. Our unique solutions focus on regulatory compliance, GRC, quality management, GLP, integrated preclinical lab management, early-stage drug discovery, content migration, and systems validation. Xybion specializes in helping companies improve their overall compliance processes and provides a complete view and prediction of organizational risk across various global operating models.

Xybion’s combination of software, business process management, and related services enable us to cover a broad spectrum of critical business needs for companies and we deliver our solutions on a global scale. Since its founding in 1977, Xybion Corporation has supported over 100 clients, through software, services, and consulting, including all the top 20 global life sciences companies. Our leadership in this dynamic and ever-changing industry has been a cornerstone of our high-value reputation.